[
  {
    "resultId": "surmount-5-weight-72w",
    "candidateId": "semaglutide:1",
    "kind": "direct_head_to_head",
    "trial": "SURMOUNT-5 (phase 3b, open-label)",
    "agents": "Tirzepatide vs semaglutide",
    "pmid": "40353578",
    "doi": "10.1056/NEJMoa2416394",
    "registryId": "NCT05822830",
    "population": "751 adults with obesity, without type 2 diabetes",
    "comparator": "Maximum tolerated dose: tirzepatide 10 or 15 mg vs semaglutide 1.7 or 2.4 mg, once weekly",
    "endpoint": "Percent change in weight from baseline to week 72",
    "followUp": "72 weeks",
    "result": "-20.2% with tirzepatide vs -13.7% with semaglutide (least-squares means; P<0.001)",
    "uncertainty": "95% CI -21.4 to -19.1 (tirzepatide); -14.9 to -12.6 (semaglutide)",
    "discontinuation": "Handled by the primary estimand: participants stay in the analysis regardless of stopping the study drug or taking other anti-obesity medication, except switching to the other study drug. Registry participant flow counts study completion, not stopping the drug: 319 of 375 (tirzepatide) and 319 of 376 (semaglutide) completed the study. The registry posts no count of participants who stopped the drug and stayed in the study.",
    "funder": "Eli Lilly",
    "registryResultsPosted": true,
    "registryMasking": "None (open-label)",
    "estimand": "Modified treatment-regimen estimand (the plan's primary): participants included regardless of treatment discontinuation or other anti-obesity medication, except switching to the other study drug. The displayed -20.2% and -13.7% match the registry's ANCOVA result over the full analysis set, which is the method the plan specifies for this estimand (§4.3.1); the publication abstract does not name the estimand, so this is verified by method, not by an explicit label.",
    "analysisPlan": {
      "title": "SURMOUNT-5 Statistical Analysis Plan v3 (approved 23 Oct 2024), ClinicalTrials.gov NCT05822830",
      "url": "https://cdn.clinicaltrials.gov/large-docs/30/NCT05822830/SAP_001.pdf",
      "sections": "§1.1 Primary estimand; §4.3.1 primary analysis; §4.3.2 efficacy-estimand analysis"
    },
    "limitations": [
      "Open-label: participants and investigators knew the assigned drug (registry masking: none).",
      "Compared maximum tolerated doses; the results apply to adults with obesity without type 2 diabetes.",
      "Funded by the manufacturer of tirzepatide."
    ],
    "citation": "SURMOUNT-5 (phase 3b, open-label). Tirzepatide vs semaglutide. Primary source: https://doi.org/10.1056/NEJMoa2416394 (PMID 40353578; NCT05822830). Cited from World Peptide Foundation, WPF Flagship Weight Management, version 1.4.0, result surmount-5-weight-72w. Versioned record: https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.4.0&resultId=surmount-5-weight-72w | Result link: https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#surmount-5-weight-72w",
    "releaseVersion": "1.4.0",
    "designLabel": "Direct head-to-head randomized trial",
    "designExplanation": "Participants in one trial were randomly assigned to tirzepatide or semaglutide, so the difference between the two arms is a direct randomized comparison.",
    "verification": {
      "verifiedOn": "2026-11-14",
      "locators": [
        {
          "claim": "-20.2% with tirzepatide and -13.7% with semaglutide at week 72",
          "source": "ClinicalTrials.gov results",
          "role": "primary",
          "locator": "Record NCT05822830, Results tab, primary outcome measure 1 (percent change in body weight, baseline to week 72): the tirzepatide arm posts -20.2 and the semaglutide arm posts -13.7, as least-squares means.",
          "url": "https://clinicaltrials.gov/study/NCT05822830?tab=results#outcome-measures",
          "status": "matched",
          "method": "scripted",
          "checkId": "ctgov-surmount5-arms",
          "note": "The registry posts standard errors, not the confidence intervals shown on this page.",
          "quotedSourceText": [
            "Percent Change From Baseline in Body Weight"
          ]
        },
        {
          "claim": "95% confidence intervals -21.4 to -19.1 and -14.9 to -12.6; P<0.001",
          "source": "PubMed abstract",
          "role": "primary",
          "locator": "Abstract, Results paragraph: reports the week-72 least-squares mean change as -20.2% (95% CI -21.4 to -19.1) for tirzepatide and -13.7% (95% CI -14.9 to -12.6) for semaglutide, P<0.001, among 751 randomized participants.",
          "url": "https://pubmed.ncbi.nlm.nih.gov/40353578/#abstract",
          "status": "matched",
          "method": "scripted",
          "checkId": "pubmed-surmount5"
        },
        {
          "claim": "Primary estimand and the method that produces the displayed values",
          "source": "Statistical analysis plan",
          "role": "primary",
          "locator": "SAP version 3 (approved 23 Oct 2024): section 1.1 defines the primary estimand and section 4.3.1 specifies the primary analysis.",
          "url": "https://cdn.clinicaltrials.gov/large-docs/30/NCT05822830/SAP_001.pdf",
          "status": "matched",
          "method": "document_read",
          "note": "The abstract does not name the estimand. The displayed values match the registry's ANCOVA result over the full analysis set, which is the method the plan specifies for its primary (modified treatment-regimen) estimand, so the match is by method, not by an explicit label."
        },
        {
          "claim": "Study completion by arm, which is how the registry reports leaving the study",
          "source": "ClinicalTrials.gov results",
          "role": "primary",
          "locator": "Record NCT05822830, Results tab, participant flow, overall study period: 375 participants started on tirzepatide and 376 on semaglutide, and 319 in each arm completed the study (56 and 57 did not). Recorded reasons for not completing, tirzepatide then semaglutide: withdrawal by subject 27 and 26, lost to follow-up 16 and 18, adverse event 6 and 6, assigned treatment by mistake 5 and 3, pregnancy 1 and 2, non-compliance with study drug 1 and 1, out of the country 0 and 1. This counts leaving the study. It is not a count of stopping the study drug while staying in the study, which the registry does not post.",
          "url": "https://clinicaltrials.gov/study/NCT05822830?tab=results",
          "status": "matched",
          "method": "scripted",
          "checkId": "ctgov-surmount5-flow"
        },
        {
          "claim": "Table or figure in the published paper that shows the displayed numbers",
          "source": "Publisher page",
          "role": "primary",
          "locator": "Publisher article page reached through the DOI 10.1056/NEJMoa2416394",
          "url": "https://doi.org/10.1056/NEJMoa2416394",
          "status": "not_read",
          "method": "document_read",
          "note": "An automated request to this address returned HTTP 403 on 2026-11-12, which shows the request was blocked; it does not show why. Europe PMC lists no open-access full text for this paper, and WPF has not established whether the article sits behind a paywall. No table or figure number is claimed."
        }
      ],
      "unverified": [
        "The table or figure in the published paper that shows these numbers: not located, because the publisher page could not be read.",
        "Treatment-discontinuation counts (stopping the study drug but staying in the study) for each arm: the registry participant flow reports study completion only, and the full text was not read.",
        "The authors' own limitations and disclosure statements: not reviewed, because the full text could not be read."
      ],
      "automatedChecks": [
        {
          "id": "pubmed-surmount5",
          "what": "The abstract reports the displayed point estimates, both confidence intervals and the sample size.",
          "method": "Re-runnable script (scripts/verification/verify-weight-management-sources.mts): fetches the PubMed record and compares the extracted abstract with the displayed values.",
          "outcome": "Passed on 2026-11-14",
          "lastRun": "2026-11-14"
        },
        {
          "id": "ctgov-surmount5-flow",
          "what": "The registry participant flow posts 375 and 376 started and 319 and 319 completed for the two arms.",
          "method": "Re-runnable script (scripts/verification/verify-weight-management-sources.mts): reads the ClinicalTrials.gov API v2 participant flow and compares the started and completed counts of both groups.",
          "outcome": "Passed on 2026-11-14",
          "lastRun": "2026-11-14"
        },
        {
          "id": "ctgov-surmount5-arms",
          "what": "The registry's primary outcome measure 1 (week 72) posts both displayed arm values.",
          "method": "Re-runnable script (scripts/verification/verify-weight-management-sources.mts): reads the ClinicalTrials.gov API v2 results record and compares posted values numerically.",
          "outcome": "Passed on 2026-11-14",
          "lastRun": "2026-11-14"
        }
      ],
      "humanReview": "none recorded"
    },
    "versionedRecordUrl": "https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.4.0&resultId=surmount-5-weight-72w",
    "analysisPlanUrl": "https://cdn.clinicaltrials.gov/large-docs/30/NCT05822830/SAP_001.pdf",
    "analysisPlanSections": "§1.1 Primary estimand; §4.3.1 primary analysis; §4.3.2 efficacy-estimand analysis",
    "registryCheckedOn": "2026-11-11",
    "detailUrl": "https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#surmount-5-weight-72w"
  },
  {
    "resultId": "step-1-weight-68w",
    "candidateId": "semaglutide:4",
    "kind": "separate_placebo_controlled",
    "trial": "STEP 1 (double-blind)",
    "agents": "Semaglutide 2.4 mg vs placebo, plus lifestyle intervention",
    "pmid": "33567185",
    "doi": "10.1056/NEJMoa2032183",
    "registryId": "NCT03548935",
    "population": "1,961 adults with BMI 30 or more (27 or more with a weight-related condition), without diabetes",
    "comparator": "Placebo plus lifestyle intervention (2:1 randomization)",
    "endpoint": "Percent change in body weight and weight reduction of at least 5% (coprimary)",
    "followUp": "68 weeks",
    "result": "-14.9% with semaglutide vs -2.4% with placebo; estimated difference -12.4 percentage points",
    "uncertainty": "Difference 95% CI -13.4 to -11.5",
    "discontinuation": "Primary estimand assessed effects regardless of treatment discontinuation or rescue interventions.",
    "funder": "Novo Nordisk",
    "registryResultsPosted": true,
    "registryMasking": "Quadruple",
    "estimand": "Treatment-policy primary estimand: effects regardless of adherence and of other anti-obesity treatment or rescue (the publication abstract's wording is \"regardless of treatment discontinuation or rescue interventions\"). The displayed difference of -12.4 points (95% CI -13.4 to -11.5) matches the registry's ANCOVA treatment difference, the method the plan specifies for this estimand. The arm values -14.9% and -2.4% are verified in the abstract only; the registry posts different, observed means.",
    "analysisPlan": {
      "title": "STEP 1 Statistical Analysis Plan (redacted, document dated 3 Jul 2020), ClinicalTrials.gov NCT03548935",
      "url": "https://cdn.clinicaltrials.gov/large-docs/35/NCT03548935/SAP_003.pdf",
      "sections": "§1.1.4 Estimands (primary estimand); §2.3.1 primary endpoint analysis"
    },
    "limitations": [
      "Both arms also received a lifestyle intervention, so the effect is of semaglutide added to lifestyle support.",
      "Enrolled adults without diabetes; not evidence for people with type 2 diabetes.",
      "Funded by the manufacturer of semaglutide."
    ],
    "citation": "STEP 1 (double-blind). Semaglutide 2.4 mg vs placebo, plus lifestyle intervention. Primary source: https://doi.org/10.1056/NEJMoa2032183 (PMID 33567185; NCT03548935). Cited from World Peptide Foundation, WPF Flagship Weight Management, version 1.4.0, result step-1-weight-68w. Versioned record: https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.4.0&resultId=step-1-weight-68w | Result link: https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#step-1-weight-68w",
    "releaseVersion": "1.4.0",
    "designLabel": "Separate placebo-controlled trial (not a head-to-head)",
    "designExplanation": "This drug was compared with placebo in its own trial. Setting two trials side by side is an indirect comparison across different populations, durations and designs, so their percentages cannot be subtracted.",
    "verification": {
      "verifiedOn": "2026-11-12",
      "locators": [
        {
          "claim": "Mean change -14.9% (semaglutide) vs -2.4% (placebo); difference -12.4 percentage points (95% CI -13.4 to -11.5)",
          "source": "PubMed abstract",
          "role": "primary",
          "locator": "Abstract, Results paragraph: reports the week-68 mean change for each arm, the estimated treatment difference with its 95% confidence interval, and P<0.001, among 1,961 randomized adults; the Methods sentence states that the primary estimand assessed effects regardless of treatment discontinuation or rescue interventions.",
          "url": "https://pubmed.ncbi.nlm.nih.gov/33567185/#abstract",
          "status": "matched",
          "method": "scripted",
          "checkId": "pubmed-step1"
        },
        {
          "claim": "Between-group treatment difference -12.4 and its 95% confidence interval -13.4 to -11.5",
          "source": "ClinicalTrials.gov results",
          "role": "primary",
          "locator": "Record NCT03548935, Results tab, primary outcome measure 1 (change in body weight, percent, baseline to week 68), analysis row for the semaglutide 2.4 mg vs placebo comparison whose group description names the treatment policy estimand: ANCOVA treatment difference -12.44, two-sided 95% CI -13.37 to -11.51, P<.0001.",
          "url": "https://clinicaltrials.gov/study/NCT03548935?tab=results#outcome-measures",
          "status": "matched",
          "method": "scripted",
          "checkId": "ctgov-step1-difference",
          "note": "Rounding to one decimal place (halves away from zero) turns the registry values into the displayed ones: -12.44 becomes -12.4, -13.37 becomes -13.4 and -11.51 becomes -11.5. The registry names this row by its estimand (treatment policy), not by an observation period. A second row (hypothetical estimand: -14.42, CI -15.29 to -13.55) exists and is not displayed.",
          "quotedSourceText": [
            "Change in Body Weight (%)",
            "Treatment policy estimand"
          ]
        },
        {
          "claim": "Arm values: the paper's modelled -14.9% and -2.4% are not the registry's observed means",
          "source": "ClinicalTrials.gov results",
          "role": "primary",
          "locator": "Same outcome measure, results by observation period: the in-trial period posts -15.6 (semaglutide) and -2.8 (placebo); the on-treatment period posts -16.9 and -3.1. These are observed means with standard deviations.",
          "url": "https://clinicaltrials.gov/study/NCT03548935?tab=results#outcome-measures",
          "status": "different_value",
          "method": "scripted",
          "checkId": "ctgov-step1-arm-means",
          "note": "The displayed -14.9% and -2.4% are the paper's modelled estimates and are verified in the abstract only. The registry does not say which observation-period figures belong to which analysis row, so pairing in-trial with the treatment policy row would be inferred, and WPF does not rely on that pairing.",
          "quotedSourceText": [
            "In-trial observation period",
            "On-treatment observation period"
          ]
        },
        {
          "claim": "Primary estimand: effects regardless of treatment discontinuation or rescue interventions",
          "source": "Statistical analysis plan",
          "role": "primary",
          "locator": "Redacted SAP (document dated 3 Jul 2020): section 1.1.4 on estimands defines the primary estimand as a treatment policy estimand (regardless of adherence and of other anti-obesity therapy); section 2.3.1 on the primary endpoint describes the ANCOVA with multiple imputation from retrieved participants.",
          "url": "https://cdn.clinicaltrials.gov/large-docs/35/NCT03548935/SAP_003.pdf",
          "status": "matched",
          "method": "document_read",
          "note": "Section numbering inside this redacted SAP is irregular: the estimand subsections are numbered 1.1.1.3 and 1.1.1.4 under 1.1.4."
        },
        {
          "claim": "Table or figure in the published paper that shows the displayed numbers",
          "source": "Publisher page",
          "role": "primary",
          "locator": "Publisher article page reached through the DOI 10.1056/NEJMoa2032183",
          "url": "https://doi.org/10.1056/NEJMoa2032183",
          "status": "not_read",
          "method": "document_read",
          "note": "An automated request to this address returned HTTP 403 on 2026-11-12, which shows the request was blocked; it does not show why. Europe PMC lists no open-access full text for this paper, and WPF has not established whether the article sits behind a paywall. No table or figure number is claimed."
        }
      ],
      "unverified": [
        "The table or figure in the published paper that shows these numbers: not located, because the publisher page could not be read.",
        "Discontinuation rates for each arm: not read from the full text.",
        "Which registry observation-period figures belong to which analysis row: the registry does not say.",
        "The authors' own limitations and disclosure statements: not reviewed, because the full text could not be read."
      ],
      "automatedChecks": [
        {
          "id": "pubmed-step1",
          "what": "The abstract reports the displayed arm values, the difference, its confidence interval, the sample size and the estimand wording.",
          "method": "Re-runnable script (scripts/verification/verify-weight-management-sources.mts): fetches the PubMed record and compares the extracted abstract with the displayed values.",
          "outcome": "Passed on 2026-11-14",
          "lastRun": "2026-11-14"
        },
        {
          "id": "ctgov-step1-difference",
          "what": "The specific registry row (treatment policy estimand, semaglutide vs placebo, ANCOVA, two-sided 95% CI) reports a difference of -12.44 with bounds -13.37 and -11.51, and each rounds to the displayed -12.4, -13.4 and -11.5.",
          "method": "Re-runnable script (scripts/verification/verify-weight-management-sources.mts): compares the estimate and both bounds of that single row numerically. The same function runs in the CI gate against a stored copy of the registry record, with a test where correct arm means and a wrong difference or bound must fail.",
          "outcome": "Passed on 2026-11-14",
          "lastRun": "2026-11-14"
        },
        {
          "id": "ctgov-step1-arm-means",
          "what": "The registry posts observed arm means of -15.6/-2.8 (in-trial) and -16.9/-3.1 (on-treatment). This is a separate claim from the treatment difference and does not support the modelled -14.9% and -2.4%.",
          "method": "Re-runnable script (scripts/verification/verify-weight-management-sources.mts): compares each posted arm value numerically.",
          "outcome": "Passed on 2026-11-14",
          "lastRun": "2026-11-14"
        }
      ],
      "humanReview": "none recorded"
    },
    "versionedRecordUrl": "https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.4.0&resultId=step-1-weight-68w",
    "analysisPlanUrl": "https://cdn.clinicaltrials.gov/large-docs/35/NCT03548935/SAP_003.pdf",
    "analysisPlanSections": "§1.1.4 Estimands (primary estimand); §2.3.1 primary endpoint analysis",
    "registryCheckedOn": "2026-11-11",
    "detailUrl": "https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#step-1-weight-68w"
  },
  {
    "resultId": "surmount-1-weight-72w",
    "candidateId": "tirzepatide:4",
    "kind": "separate_placebo_controlled",
    "trial": "SURMOUNT-1 (phase 3, double-blind)",
    "agents": "Tirzepatide 5, 10 or 15 mg vs placebo",
    "pmid": "35658024",
    "doi": "10.1056/NEJMoa2206038",
    "registryId": "NCT04184622",
    "population": "2,539 adults with BMI 30 or more, or 27 or more with a weight-related complication, excluding diabetes",
    "comparator": "Placebo (1:1:1:1 randomization), including a 20-week dose-escalation period",
    "endpoint": "Percent change in weight and weight reduction of 5% or more (coprimary)",
    "followUp": "72 weeks",
    "result": "-15.0%, -19.5% and -20.9% with 5, 10 and 15 mg vs -3.1% with placebo",
    "uncertainty": "95% CI -15.9 to -14.2, -20.4 to -18.5, -21.8 to -19.9; placebo -4.3 to -1.9",
    "discontinuation": "Treatment-regimen estimand assessed effects regardless of treatment discontinuation, intention-to-treat population.",
    "funder": "Eli Lilly",
    "registryResultsPosted": true,
    "registryMasking": "Double",
    "estimand": "The abstract states a treatment-regimen estimand (regardless of treatment discontinuation, intention-to-treat). The analysis plan calls the matching estimand \"hybrid\" (regardless of adherence; ANCOVA with multiple imputation, §6.13.1.2). The registry's posted results (-16.0%, -21.4%, -22.5% vs -2.4%) are a different, efficacy-style analysis that excludes data after drug was stopped, so they do not check the displayed values. The plan also says publications would follow the efficacy estimand, and the protocol assigns the efficacy estimand to all purposes other than the FDA submission, which differs from the abstract; this is reported, not resolved.",
    "analysisPlan": {
      "title": "SURMOUNT-1 Statistical Analysis Plan version 2 (28 Sep 2021), ClinicalTrials.gov NCT04184622",
      "url": "https://cdn.clinicaltrials.gov/large-docs/22/NCT04184622/SAP_001.pdf",
      "sections": "§6.2 General Considerations (estimands); §6.13 Efficacy Analyses; §6.13.1.1 efficacy estimand; §6.13.1.2 hybrid estimand"
    },
    "limitations": [
      "Enrolled adults without diabetes; not evidence for people with type 2 diabetes.",
      "The 72-week period included a 20-week dose escalation, so full-dose exposure was shorter than 72 weeks.",
      "Funded by the manufacturer of tirzepatide."
    ],
    "citation": "SURMOUNT-1 (phase 3, double-blind). Tirzepatide 5, 10 or 15 mg vs placebo. Primary source: https://doi.org/10.1056/NEJMoa2206038 (PMID 35658024; NCT04184622). Cited from World Peptide Foundation, WPF Flagship Weight Management, version 1.4.0, result surmount-1-weight-72w. Versioned record: https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.4.0&resultId=surmount-1-weight-72w | Result link: https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#surmount-1-weight-72w",
    "releaseVersion": "1.4.0",
    "designLabel": "Separate placebo-controlled trial (not a head-to-head)",
    "designExplanation": "This drug was compared with placebo in its own trial. Setting two trials side by side is an indirect comparison across different populations, durations and designs, so their percentages cannot be subtracted.",
    "verification": {
      "verifiedOn": "2026-11-12",
      "locators": [
        {
          "claim": "-15.0%, -19.5% and -20.9% (5, 10, 15 mg) vs -3.1% (placebo) at week 72, with confidence intervals",
          "source": "PubMed abstract",
          "role": "primary",
          "locator": "Abstract, Results paragraph: reports the week-72 mean percentage change for each tirzepatide dose and placebo with 95% confidence intervals, among 2,539 randomized adults; the Methods sentence names the treatment-regimen estimand, regardless of treatment discontinuation, in the intention-to-treat population.",
          "url": "https://pubmed.ncbi.nlm.nih.gov/35658024/#abstract",
          "status": "matched",
          "method": "scripted",
          "checkId": "pubmed-surmount1"
        },
        {
          "claim": "The same values, printed on a reproduction of the paper's figure",
          "source": "Public reproduction (corroboration only)",
          "role": "corroboration",
          "locator": "ASN Nutrition 2025 conference slides (Gulati), PDF page 22 of 33: reproduces a figure from the NEJM paper. Panel A, whose printed title is overall percent change in body weight from baseline (treatment-regimen estimand), shows -15.0, -19.5 and -20.9 for tirzepatide 5, 10 and 15 mg and -3.1 for placebo. Panel C, with the same estimand label, shows weight-reduction targets.",
          "url": "https://nutrition.org/wp-content/uploads/2025/05/Session-1-2-Gulati-Updated-ASN-Orlando-2025.GULATI.-Patient-Selection-GLP-1RA.pdf",
          "status": "matched",
          "method": "document_read",
          "note": "Corroboration only: a third-party slide, not the paper and not a primary source. WPF read the rendered slide image directly (there is no machine-readable text layer), so this is not scripted. The slide shows no figure number, so the figure number in the original paper is unverified.",
          "quotedSourceText": [
            "Overall Percent Change in Body Weight from Baseline (treatment-regimen estimand)"
          ]
        },
        {
          "claim": "The registry's posted primary result is a different analysis",
          "source": "ClinicalTrials.gov results",
          "role": "primary",
          "locator": "Record NCT04184622, Results tab, primary outcome measure 1 (percent change in body weight, primary treatment period, week 72): posts -16.0 (5 mg), -21.4 (10 mg), -22.5 (15 mg) and -2.4 (placebo).",
          "url": "https://clinicaltrials.gov/study/NCT04184622?tab=results#outcome-measures",
          "status": "different_value",
          "method": "scripted",
          "checkId": "ctgov-surmount1-registry",
          "note": "These are not the displayed values and cannot verify them. The registry's own population description says data after study drug was stopped are excluded, so this is an efficacy-style analysis, while the displayed values come from the paper's treatment-regimen analysis, which includes data regardless of discontinuation. The two analyses answer different questions, so a difference between them is expected.",
          "quotedSourceText": [
            "Percent Change From Baseline in Body Weight (Primary Treatment Period)"
          ]
        },
        {
          "claim": "Which estimand each set of numbers belongs to",
          "source": "Statistical analysis plan",
          "role": "primary",
          "locator": "SAP version 2 (28 Sep 2021): section 6.2 introduces two estimands, efficacy and hybrid; the opening of section 6.13 says which guides which purpose; section 6.13.1.1 specifies the efficacy-estimand analysis (mixed model, efficacy analysis set); section 6.13.1.2 specifies the hybrid-estimand analysis (ANCOVA with multiple imputation, full analysis set, regardless of adherence).",
          "url": "https://cdn.clinicaltrials.gov/large-docs/22/NCT04184622/SAP_001.pdf",
          "status": "matched",
          "method": "document_read",
          "note": "The abstract's treatment-regimen estimand corresponds in content to the plan's hybrid estimand; the plan does not use the label treatment-regimen. The plan also says publications would be guided by the efficacy estimand, and the protocol assigns the efficacy estimand to all purposes other than the FDA submission, yet the abstract headlines the treatment-regimen values. The audit of 2026-11-12 found no accessible primary source that resolves this, so it stays an open question."
        },
        {
          "claim": "Which analysis the protocol assigns to which purpose",
          "source": "Study protocol",
          "role": "primary",
          "locator": "Protocol amendment b (approved 4 Oct 2021), section 9.4.3.1 on primary analyses: defines the efficacy and hybrid estimands; the primary efficacy analysis for the FDA is guided by the hybrid estimand (full analysis set, ANCOVA with multiple imputation) and, for all other purposes, by the efficacy estimand (efficacy analysis set, mixed model). Section 10.1.10 leaves the publication policy to the Clinical Trial Agreement.",
          "url": "https://cdn.clinicaltrials.gov/large-docs/22/NCT04184622/Prot_000.pdf",
          "status": "matched",
          "method": "document_read",
          "note": "Agrees with the analysis plan on the two estimands. The protocol does not mention publications by name; only the analysis plan does. Neither document explains why the paper headlines the treatment-regimen values, which correspond to the hybrid estimand."
        },
        {
          "claim": "Table or figure in the published paper that shows the displayed numbers",
          "source": "Publisher page",
          "role": "primary",
          "locator": "Publisher article page reached through the DOI 10.1056/NEJMoa2206038",
          "url": "https://doi.org/10.1056/NEJMoa2206038",
          "status": "not_read",
          "method": "document_read",
          "note": "An automated request to this address returned HTTP 403 on 2026-11-12, which shows the request was blocked; it does not show why. Europe PMC lists no open-access full text for this paper, and WPF has not established whether the article sits behind a paywall. No table or figure number is claimed."
        }
      ],
      "unverified": [
        "The table or figure in the published paper that shows these numbers: not located, because the publisher page could not be read.",
        "The figure number in the original paper for the reproduced panel: unverified.",
        "Whether the paper's body also reports the efficacy-estimand values: not checked, because the publisher page could not be read.",
        "Why the paper headlines the treatment-regimen (hybrid) values although the analysis plan names publications, and the protocol names all purposes other than the FDA submission, as efficacy-estimand uses: unresolved. The best remaining source is the paper's own Methods, which the publisher page did not let WPF read.",
        "The authors' own limitations and disclosure statements: not reviewed, because the full text could not be read."
      ],
      "automatedChecks": [
        {
          "id": "pubmed-surmount1",
          "what": "The abstract reports the displayed values for all three doses and placebo, their confidence intervals, the sample size and the treatment-regimen estimand wording.",
          "method": "Re-runnable script (scripts/verification/verify-weight-management-sources.mts): fetches the PubMed record and compares the extracted abstract with the displayed values.",
          "outcome": "Passed on 2026-11-14",
          "lastRun": "2026-11-14"
        },
        {
          "id": "ctgov-surmount1-registry",
          "what": "The registry's primary outcome measure 1 posts -16.0, -21.4, -22.5 and -2.4, and does not post any of the displayed -15.0, -19.5, -20.9 or -3.1.",
          "method": "Re-runnable script (scripts/verification/verify-weight-management-sources.mts): reads the ClinicalTrials.gov API v2 results record and checks presence and absence of values numerically.",
          "outcome": "Passed on 2026-11-12: the registry reports different values by design (see above)",
          "lastRun": "2026-11-14"
        }
      ],
      "humanReview": "none recorded"
    },
    "versionedRecordUrl": "https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.4.0&resultId=surmount-1-weight-72w",
    "analysisPlanUrl": "https://cdn.clinicaltrials.gov/large-docs/22/NCT04184622/SAP_001.pdf",
    "analysisPlanSections": "§6.2 General Considerations (estimands); §6.13 Efficacy Analyses; §6.13.1.1 efficacy estimand; §6.13.1.2 hybrid estimand",
    "registryCheckedOn": "2026-11-11",
    "detailUrl": "https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#surmount-1-weight-72w"
  },
  {
    "resultId": "retatrutide-phase2-weight-48w",
    "candidateId": "retatrutide:2",
    "kind": "separate_placebo_controlled",
    "trial": "Retatrutide phase 2 (double-blind)",
    "agents": "Retatrutide 1, 4, 8 or 12 mg vs placebo",
    "pmid": "37366315",
    "doi": "10.1056/NEJMoa2301972",
    "registryId": "NCT04881760",
    "population": "338 adults with BMI 30 or more, or 27 to under 30 plus at least one weight-related condition",
    "comparator": "Placebo (multiple dose arms, 2:1:1:1:1:2:2 randomization)",
    "endpoint": "Primary: percent change in body weight at 24 weeks. Secondary: at 48 weeks",
    "followUp": "48 weeks (primary endpoint at 24 weeks)",
    "result": "At 48 weeks: -8.7% (1 mg), -17.1% (4 mg), -22.8% (8 mg), -24.2% (12 mg) vs -2.1% placebo",
    "uncertainty": "Not reported in the abstract. ClinicalTrials.gov posts differences from placebo at week 48 (95% CI): 1 mg -6.57 (-8.94 to -4.20); 12 mg -22.11 (-24.92 to -19.31). The 4 mg and 8 mg groups are posted separately by starting dose.",
    "discontinuation": "Handled by a hypothetical strategy: the primary (efficacy) estimand asks what the effect would be had participants adhered, and the registry's 48-week results use a model that excludes data after permanent discontinuation. Registry participant flow counts study completion, not stopping the drug: placebo 50 of 70, 1 mg 60 of 69, 4 mg 52 of 67, 8 mg 59 of 70, 12 mg 54 of 62 (by starting-dose arm). The registry posts no count of participants who stopped the drug and stayed in the study.",
    "funder": "Eli Lilly",
    "registryResultsPosted": true,
    "registryMasking": "Double",
    "estimand": "Efficacy estimand: the plan's primary estimand, also applied to the 48-week secondary endpoint. Permanent discontinuation of study drug is handled by a hypothetical strategy, asking what the effect would be had participants adhered to treatment. The registry's 24- and 48-week results use a mixed-effects model that excludes data after discontinuation, consistent with this; the displayed 48-week values match the registry's secondary measure.",
    "analysisPlan": {
      "title": "Retatrutide phase 2 Statistical Analysis Plan V4.0 (approved 15 Dec 2022), ClinicalTrials.gov NCT04881760",
      "url": "https://cdn.clinicaltrials.gov/large-docs/60/NCT04881760/SAP_001.pdf",
      "sections": "§1.1 Primary estimand and estimands for secondary objectives; §4.3.2 main analytical approach"
    },
    "limitations": [
      "Phase 2 dose-finding trial of 338 adults split across seven arms, so each arm is small.",
      "The primary endpoint was at 24 weeks; the 48-week results are secondary.",
      "Funded by the manufacturer of retatrutide. A phase 3 outcome is not represented here."
    ],
    "citation": "Retatrutide phase 2 (double-blind). Retatrutide 1, 4, 8 or 12 mg vs placebo. Primary source: https://doi.org/10.1056/NEJMoa2301972 (PMID 37366315; NCT04881760). Cited from World Peptide Foundation, WPF Flagship Weight Management, version 1.4.0, result retatrutide-phase2-weight-48w. Versioned record: https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.4.0&resultId=retatrutide-phase2-weight-48w | Result link: https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#retatrutide-phase2-weight-48w",
    "releaseVersion": "1.4.0",
    "designLabel": "Separate placebo-controlled trial (not a head-to-head)",
    "designExplanation": "This drug was compared with placebo in its own trial. Setting two trials side by side is an indirect comparison across different populations, durations and designs, so their percentages cannot be subtracted.",
    "verification": {
      "verifiedOn": "2026-11-14",
      "locators": [
        {
          "claim": "48-week least-squares mean change: -8.7% (1 mg), -17.1% (4 mg), -22.8% (8 mg), -24.2% (12 mg) vs -2.1% (placebo)",
          "source": "PubMed abstract",
          "role": "primary",
          "locator": "Abstract, Results paragraph: reports the 48-week least-squares mean percentage change for the 1 mg group, the combined 4 mg group, the combined 8 mg group, the 12 mg group and placebo, among 338 enrolled adults.",
          "url": "https://pubmed.ncbi.nlm.nih.gov/37366315/#abstract",
          "status": "matched",
          "method": "scripted",
          "checkId": "pubmed-retatrutide"
        },
        {
          "claim": "The same 48-week values in the registry",
          "source": "ClinicalTrials.gov results",
          "role": "primary",
          "locator": "Record NCT04881760, Results tab, first secondary outcome measure for mean percent change in body weight at week 48: placebo -2.11, 1 mg -8.67 and 12 mg -24.22; the 4 mg and 8 mg groups are posted as separate starting-dose arms (-16.32 and -17.83; -21.72 and -23.88).",
          "url": "https://clinicaltrials.gov/study/NCT04881760?tab=results#outcome-measures",
          "status": "matched",
          "method": "scripted",
          "checkId": "ctgov-retatrutide-w48",
          "note": "The primary outcome (week 24) is outcome measure 1 in the registry; the week-48 measure is the first secondary.",
          "quotedSourceText": [
            "Mean Percent Change From Baseline in Body Weight"
          ]
        },
        {
          "claim": "Uncertainty shown on this page: differences from placebo with 95% confidence intervals",
          "source": "ClinicalTrials.gov results",
          "role": "primary",
          "locator": "Same outcome measure, statistical analyses: the 1 mg arm vs placebo posts a least-squares mean difference of -6.57 (95% CI -8.94 to -4.20); the 12 mg arm vs placebo posts -22.11 (95% CI -24.92 to -19.31).",
          "url": "https://clinicaltrials.gov/study/NCT04881760?tab=results#outcome-measures",
          "status": "matched",
          "method": "scripted",
          "checkId": "ctgov-retatrutide-diff-1mg",
          "note": "These are differences from placebo, not confidence intervals around each arm's own mean. A second check covers the 12 mg row."
        },
        {
          "claim": "Primary estimand (efficacy; hypothetical strategy for permanent discontinuation) applies to the 48-week estimate",
          "source": "Statistical analysis plan",
          "role": "primary",
          "locator": "SAP version 4.0 (15 Dec 2022): section 1.1 defines the primary estimand and the estimands for secondary objectives; section 4.3.2 describes the main analytical approach.",
          "url": "https://cdn.clinicaltrials.gov/large-docs/60/NCT04881760/SAP_001.pdf",
          "status": "matched",
          "method": "document_read",
          "note": "The registry population excludes data after discontinuation of study drug, consistent with the hypothetical strategy."
        },
        {
          "claim": "Study completion by starting arm, which is how the registry reports leaving the study",
          "source": "ClinicalTrials.gov results",
          "role": "primary",
          "locator": "Record NCT04881760, Results tab, participant flow, overall study period: 338 participants started across seven starting arms. Completed the study out of started: placebo 50 of 70, 1 mg 60 of 69, 4 mg 26 of 33 and 26 of 34 (52 of 67), 8 mg 30 of 35 and 29 of 35 (59 of 70), 12 mg 54 of 62. In the placebo arm 13 of the 20 who did not complete withdrew by their own choice. This counts leaving the study. It is not a count of stopping the study drug while staying in the study, which the registry does not post.",
          "url": "https://clinicaltrials.gov/study/NCT04881760?tab=results",
          "status": "matched",
          "method": "scripted",
          "checkId": "ctgov-retatrutide-flow"
        },
        {
          "claim": "Table or figure in the published paper that shows the displayed numbers",
          "source": "Publisher page",
          "role": "primary",
          "locator": "Publisher article page reached through the DOI 10.1056/NEJMoa2301972",
          "url": "https://doi.org/10.1056/NEJMoa2301972",
          "status": "not_read",
          "method": "document_read",
          "note": "An automated request to this address returned HTTP 403 on 2026-11-12, which shows the request was blocked; it does not show why. Europe PMC lists no open-access full text for this paper, and WPF has not established whether the article sits behind a paywall. No table or figure number is claimed."
        }
      ],
      "unverified": [
        "The table or figure in the published paper that shows these numbers: not located, because the publisher page could not be read.",
        "Confidence intervals for the combined 4 mg and 8 mg groups: the registry posts them by starting-dose arm, so no source value for the combined groups was read.",
        "Treatment-discontinuation counts (stopping the study drug but staying in the study): the registry participant flow reports study completion only, and the full text was not read.",
        "The authors' own limitations and disclosure statements: not reviewed, because the full text could not be read."
      ],
      "automatedChecks": [
        {
          "id": "ctgov-retatrutide-flow",
          "what": "The registry participant flow posts the started and completed counts of all seven starting arms (338 started in total).",
          "method": "Re-runnable script (scripts/verification/verify-weight-management-sources.mts): reads the ClinicalTrials.gov API v2 participant flow and compares the started and completed counts of every group.",
          "outcome": "Passed on 2026-11-14",
          "lastRun": "2026-11-14"
        },
        {
          "id": "pubmed-retatrutide",
          "what": "The abstract reports all five displayed week-48 values and the sample size.",
          "method": "Re-runnable script (scripts/verification/verify-weight-management-sources.mts): fetches the PubMed record and compares the extracted abstract with the displayed values.",
          "outcome": "Passed on 2026-11-14",
          "lastRun": "2026-11-14"
        },
        {
          "id": "ctgov-retatrutide-w48",
          "what": "The registry's week-48 measure posts the placebo, 1 mg and 12 mg values and the four starting-dose arm values.",
          "method": "Re-runnable script (scripts/verification/verify-weight-management-sources.mts): reads the ClinicalTrials.gov API v2 results record and compares posted values numerically.",
          "outcome": "Passed on 2026-11-14",
          "lastRun": "2026-11-14"
        },
        {
          "id": "ctgov-retatrutide-diff-1mg",
          "what": "The registry's analysis rows for 1 mg vs placebo (-6.57; -8.94 to -4.20) and 12 mg vs placebo (-22.11; -24.92 to -19.31) report the displayed estimates and both bounds, 95% two-sided.",
          "method": "Re-runnable script (scripts/verification/verify-weight-management-sources.mts): compares estimate and both bounds of each row numerically (the 12 mg row is check ctgov-retatrutide-diff-12mg).",
          "outcome": "Passed on 2026-11-14",
          "lastRun": "2026-11-14"
        },
        {
          "id": "pooled-retatrutide-4mg",
          "what": "The participant-weighted mean of the two registry 4 mg arms (33 and 33 participants) is consistent with the combined -17.1.",
          "method": "WPF arithmetic in the same script; the source does not state this pooling.",
          "outcome": "-17.07: consistent (2026-11-12)",
          "lastRun": "2026-11-14"
        },
        {
          "id": "pooled-retatrutide-8mg",
          "what": "The participant-weighted mean of the two registry 8 mg arms (35 and 35 participants) is consistent with the combined -22.8.",
          "method": "WPF arithmetic in the same script; the source does not state this pooling.",
          "outcome": "-22.80: consistent (2026-11-12)",
          "lastRun": "2026-11-14"
        }
      ],
      "humanReview": "none recorded"
    },
    "versionedRecordUrl": "https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.4.0&resultId=retatrutide-phase2-weight-48w",
    "analysisPlanUrl": "https://cdn.clinicaltrials.gov/large-docs/60/NCT04881760/SAP_001.pdf",
    "analysisPlanSections": "§1.1 Primary estimand and estimands for secondary objectives; §4.3.2 main analytical approach",
    "registryCheckedOn": "2026-11-11",
    "detailUrl": "https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#retatrutide-phase2-weight-48w"
  },
  {
    "resultId": "jama-intern-med-2024-realworld",
    "candidateId": "tirzepatide:6",
    "kind": "observational_cohort",
    "trial": "Rodriguez and colleagues, JAMA Internal Medicine 2024: cohort study, not a randomized trial",
    "agents": "Tirzepatide vs semaglutide (formulations labeled for type 2 diabetes, on or off label)",
    "pmid": "38976257",
    "doi": "10.1001/jamainternmed.2024.2525",
    "registryId": null,
    "population": "41,222 US adults with overweight or obesity on semaglutide (32,029) or tirzepatide (9,193); 18,386 after propensity-score matching; 52.0% of the matched group had type 2 diabetes",
    "comparator": "Semaglutide vs tirzepatide, as prescribed",
    "endpoint": "On-treatment weight change at 3, 6 and 12 months",
    "followUp": "Up to 12 months, on-treatment",
    "result": "Tirzepatide users were more likely to reach 5%, 10% and 15% weight loss (hazard ratios 1.76, 2.54, 3.24)",
    "uncertainty": "Hazard-ratio 95% CIs 1.68-1.84, 2.37-2.73, 2.91-3.61. Weight differences favoring tirzepatide: -2.4% (95% CI -2.5 to -2.2) at 3 months, -4.3% (-4.7 to -4.0) at 6 months, -6.9% (-7.9 to -5.8) at 12 months",
    "discontinuation": "On-treatment analysis: follow-up ended at discontinuation for 55.9% (tirzepatide) and 52.5% (semaglutide), so results describe people while taking the drug and are not comparable to the intention-to-treat results above.",
    "funder": "Not identified: the full text names no funder and has no funding statement (author affiliations are not treated as the funder).",
    "registryResultsPosted": null,
    "registryMasking": null,
    "estimand": "Observational cohort, so there is no randomized treatment-regimen or efficacy estimand. The Methods name on-treatment weight loss as the primary estimand of interest: follow-up was censored at the first of treatment discontinuation (30 or more days without medication on hand), switching to a different GLP-1 receptor agonist, last encounter, or study end (3 Nov 2023), and unobserved weights were assumed missing at random. The displayed numbers are this primary on-treatment analysis, so they describe patients while they were taking the drug (follow-up ended at discontinuation for 55.9% of the tirzepatide and 52.5% of the semaglutide group). A separate modified intention-to-treat sensitivity analysis ignored censoring for discontinuation and switching; the supplement reports smaller weight reductions and somewhat attenuated treatment effects, the Discussion describes the differences between the drugs as similar, and it is not the source of any number shown here. Matching cannot remove unmeasured confounding, which the authors acknowledge.",
    "analysisPlan": null,
    "limitations": [
      "Observational and not randomized: matched groups can still differ in ways that were not measured.",
      "On-treatment analysis, so results describe people while they were taking the drug.",
      "Formulations labeled for type 2 diabetes were used on or off label, and 52.0% of the matched group had type 2 diabetes."
    ],
    "citation": "Rodriguez and colleagues, JAMA Internal Medicine 2024: cohort study, not a randomized trial. Tirzepatide vs semaglutide (formulations labeled for type 2 diabetes, on or off label). Primary source: https://doi.org/10.1001/jamainternmed.2024.2525 (PMID 38976257). Cited from World Peptide Foundation, WPF Flagship Weight Management, version 1.4.0, result jama-intern-med-2024-realworld. Versioned record: https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.4.0&resultId=jama-intern-med-2024-realworld | Result link: https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#jama-intern-med-2024-realworld",
    "releaseVersion": "1.4.0",
    "designLabel": "Observational cohort (not randomized)",
    "designExplanation": "Patients were not randomized. People who chose or were prescribed each drug were matched statistically, so differences can reflect factors that were not measured. Results describe time on treatment only.",
    "verification": {
      "verifiedOn": "2026-11-14",
      "locators": [
        {
          "claim": "Population: 41,222 adults (32,029 semaglutide; 9,193 tirzepatide); 18,386 after matching; 9,563 (52.0%) with type 2 diabetes",
          "source": "Open-access full text",
          "role": "primary",
          "locator": "Results, first paragraph under patient characteristics, and Figure 1 (study flow diagram); matched-cohort characteristics are in the Table.",
          "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11231910/",
          "status": "matched",
          "method": "scripted",
          "checkId": "pmc-jama-population",
          "note": "Read in the PubMed Central copy, which Europe PMC lists as open access (CC BY-NC-ND)."
        },
        {
          "claim": "Hazard ratios 1.76, 2.54 and 3.24 for reaching 5%, 10% and 15% weight loss, with confidence intervals (exact values)",
          "source": "Open-access full text",
          "role": "primary",
          "locator": "Results paragraph on weight-loss thresholds, and the Abstract: the hazard ratios and their 95% confidence intervals are printed in the text.",
          "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11231910/",
          "status": "matched",
          "method": "scripted",
          "checkId": "pmc-jama-hazard-ratios",
          "note": "The article body points to Figure 3 after the hazard-ratio sentence, but the Figure 3 caption describes mean changes within each treatment group and Figure 2 shows event probabilities; the Figure 4 caption and image show the hazard ratios, so WPF follows the figure itself."
        },
        {
          "claim": "Hazard ratios, as plotted for the overall matched cohort",
          "source": "Open-access full text",
          "role": "primary",
          "locator": "Figure 4, panels A to C. Panel A plots the hazard of 5% or greater weight loss, panel B 10% or greater and panel C 15% or greater, each as tirzepatide vs semaglutide. In every panel the category labelled All is the overall matched cohort, shown beside the T2D and No T2D categories.",
          "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11231910/#ioi240039f4",
          "status": "matched",
          "method": "document_read",
          "note": "Read from the figure image in the PubMed Central open-data copy (file md5 matches the bucket manifest). The figure prints no values, so the All points were read by eye as consistent with 1.76, 2.54 and 3.24; exact values come from the text.",
          "quotedSourceText": [
            "All",
            "T2D",
            "No T2D"
          ]
        },
        {
          "claim": "Adjusted weight differences -2.4%, -4.3% and -6.9% at 3, 6 and 12 months, with confidence intervals (exact values)",
          "source": "Open-access full text",
          "role": "primary",
          "locator": "Results paragraph on on-treatment weight change after adjusting for residual confounding, and the Abstract: the differences and their 95% confidence intervals are printed in the text.",
          "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11231910/",
          "status": "matched",
          "method": "scripted",
          "checkId": "pmc-jama-differences",
          "note": "The article body cites Figure 3 after this sentence; Figure 3 shows mean changes within each treatment group, not differences. The differences are plotted in Figure 4."
        },
        {
          "claim": "Adjusted differences, as plotted for the overall matched cohort",
          "source": "Open-access full text",
          "role": "primary",
          "locator": "Figure 4, panels D to F. Panel D plots the difference in percentage change in body weight at 3 months, panel E at 6 months and panel F at 12 months, tirzepatide vs semaglutide among matched patients still on treatment. In every panel the category labelled All is the overall matched cohort, beside the T2D and No T2D categories.",
          "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11231910/#ioi240039f4",
          "status": "matched",
          "method": "document_read",
          "note": "Read from the same figure image. The figure prints no values, so the All points were read by eye as consistent with -2.4, -4.3 and -6.9; exact values come from the text.",
          "quotedSourceText": [
            "All",
            "T2D",
            "No T2D"
          ]
        },
        {
          "claim": "Follow-up ended by discontinuation for 55.9% (tirzepatide) and 52.5% (semaglutide)",
          "source": "Open-access full text",
          "role": "primary",
          "locator": "Results, patient characteristics paragraph (5,140 and 4,823 patients).",
          "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11231910/",
          "status": "matched",
          "method": "scripted",
          "checkId": "pmc-jama-discontinuation"
        },
        {
          "claim": "Estimand and censoring",
          "source": "Open-access full text",
          "role": "primary",
          "locator": "Methods, weight outcomes paragraph: names on-treatment weight loss as the primary estimand of interest, with follow-up censored at the first of treatment discontinuation (30 or more days without medication on hand), switching to a different GLP-1 receptor agonist, last encounter, or study end (3 Nov 2023). Methods, sensitivity analyses: a modified intention-to-treat analysis ignored censoring for discontinuation and switching and used all available follow-up weights.",
          "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11231910/",
          "status": "matched",
          "method": "scripted",
          "checkId": "pmc-jama-estimand",
          "note": "The displayed numbers come from the primary on-treatment analysis. The modified intention-to-treat result is in the paper's supplement figures, which WPF did not read; the authors' Discussion says it showed smaller weight reductions with similar differences between the drugs."
        },
        {
          "claim": "The modified intention-to-treat sensitivity analysis",
          "source": "Open-access full text",
          "role": "primary",
          "locator": "Supplement 2, sections 2.1.1 and 2.1.2 on sensitivity analyses (eFigures 3 to 6): in the modified intention-to-treat analysis, where only administrative censoring applied, fewer patients reached the 5%, 10% and 15% weight-loss thresholds, weight reductions were smaller at every time point, and treatment effects were described as somewhat attenuated.",
          "url": "https://pmc-oa-opendata.s3.amazonaws.com/PMC11231910.1/jamainternmed-e242525-s002.pdf",
          "status": "matched",
          "method": "document_read",
          "note": "Supplement text was read; the plotted eFigure values were not extracted. The Discussion of the paper separately describes the differences between the two drugs as similar under this analysis; the supplement wording is somewhat attenuated, and both are recorded."
        },
        {
          "claim": "The authors' own limitations and disclosures",
          "source": "Open-access full text",
          "role": "primary",
          "locator": "Discussion, Strengths and Limitations paragraph; end matter, Conflict of Interest Disclosures and Author Contributions.",
          "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11231910/",
          "status": "matched",
          "method": "scripted",
          "checkId": "pmc-jama-author-statements",
          "note": "See the authors' statements below. No funding or role-of-funder statement was found."
        },
        {
          "claim": "Publisher article page",
          "source": "Publisher page",
          "role": "primary",
          "locator": "JAMA Network article page for this paper (the PubMed Central copy above was read instead).",
          "url": "https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2821080",
          "status": "not_read",
          "method": "document_read",
          "note": "An automated request to this address returned HTTP 403 on 2026-11-12, which shows the request was blocked. WPF read the open-access PubMed Central copy instead and did not compare it line by line with the publisher page."
        }
      ],
      "unverified": [
        "Exact plotted values in Figure 4 and in the supplement's eFigures: the figures print no values (Figure 4) or were not extracted (eFigures), so only the text values are verified numbers.",
        "Funder: the full text names no funder and contains no funding or role-of-funder statement, so it is left unidentified. Author affiliations are not treated as the funder."
      ],
      "automatedChecks": [
        {
          "id": "pmc-jama-population",
          "what": "The full text reports the displayed cohort sizes and the 52.0% type 2 diabetes share.",
          "method": "Re-runnable script (scripts/verification/verify-weight-management-sources.mts): fetches the Europe PMC full-text XML, strips markup and matches fragments.",
          "outcome": "Passed on 2026-11-14",
          "lastRun": "2026-11-14"
        },
        {
          "id": "pmc-jama-hazard-ratios",
          "what": "The full text reports the three hazard ratios and their confidence limits.",
          "method": "Re-runnable script (scripts/verification/verify-weight-management-sources.mts): fetches the Europe PMC full-text XML and matches fragments.",
          "outcome": "Passed on 2026-11-14",
          "lastRun": "2026-11-14"
        },
        {
          "id": "pmc-jama-differences",
          "what": "The full text reports the three adjusted differences and the 12-month interval.",
          "method": "Re-runnable script (scripts/verification/verify-weight-management-sources.mts): fetches the Europe PMC full-text XML and matches fragments.",
          "outcome": "Passed on 2026-11-14",
          "lastRun": "2026-11-14"
        },
        {
          "id": "pmc-jama-discontinuation",
          "what": "The full text reports the two discontinuation shares and counts.",
          "method": "Re-runnable script (scripts/verification/verify-weight-management-sources.mts): fetches the Europe PMC full-text XML and matches fragments.",
          "outcome": "Passed on 2026-11-14",
          "lastRun": "2026-11-14"
        },
        {
          "id": "pmc-jama-figure-captions",
          "what": "The captions of Figures 2, 3 and 4 say what the page states they show, including that Figure 4 panels A to C hold hazard ratios and panels D to F hold absolute differences.",
          "method": "Re-runnable script (scripts/verification/verify-weight-management-sources.mts): fetches the Europe PMC full-text XML and matches caption fragments.",
          "outcome": "Passed on 2026-11-14",
          "lastRun": "2026-11-14"
        },
        {
          "id": "figure4-image-read",
          "what": "In the Figure 4 image, panels A to C are titled as hazard of weight loss at 5%, 10% and 15% or greater, panels D to F as the difference at 3, 6 and 12 months, and each panel has categories All, T2D and No T2D.",
          "method": "WPF read the downloaded image visually (not scripted, no text extraction). The file's md5 matches the PubMed Central open-data manifest.",
          "outcome": "Read on 2026-11-12; matches the caption",
          "lastRun": "2026-11-12"
        },
        {
          "id": "pmc-jama-estimand",
          "what": "The Methods name on-treatment weight loss as the primary estimand, list the censoring events, and describe the modified intention-to-treat sensitivity analysis.",
          "method": "Re-runnable script (scripts/verification/verify-weight-management-sources.mts): fetches the Europe PMC full-text XML and matches fragments.",
          "outcome": "Passed on 2026-11-14",
          "lastRun": "2026-11-14"
        },
        {
          "id": "pmc-jama-author-statements",
          "what": "The limitations and disclosure statements summarized below are present in the full text, and no funding or role-of-funder heading exists in it.",
          "method": "Re-runnable script (scripts/verification/verify-weight-management-sources.mts): fetches the Europe PMC full-text XML, matches fragments and asserts the absence of funding headings.",
          "outcome": "Passed on 2026-11-14",
          "lastRun": "2026-11-14"
        }
      ],
      "humanReview": "none recorded",
      "authorStatements": {
        "source": "Open-access full text (PubMed Central copy), Discussion and end matter, read on 2026-11-12. Paraphrased by WPF.",
        "limitations": [
          "Informative censoring is possible, because patients can see their own weight loss and those seeing none may be more likely to stop or switch drugs. In the modified intention-to-treat analysis the authors' Discussion describes similar differences between the two drugs, while the supplement describes smaller weight reductions and somewhat attenuated treatment effects.",
          "Unmeasured confounding may exist, especially the degree of motivation for weight loss; the authors say a substantial amount would be needed to negate the estimates.",
          "Electronic health record data: adverse events are likely underreported, and weights are recorded only at visits, so event times are likely delayed (the authors expect this to affect both groups similarly).",
          "The imputation model assumed missingness depended only on observed information, which may bias results if unmeasured variables contributed.",
          "Brand was used as a proxy for target dose, so patients may have received doses above or below standard doses.",
          "Health system and payer information were unavailable; the sample covered 35 states but is not representative of the US, which limits generalizability.",
          "Only medications labeled for type 2 diabetes were included."
        ],
        "disclosures": [
          "One author reported consulting fees from Premier outside the submitted work; no other disclosures were reported."
        ],
        "funding": "Not identified. The full text has no funding or role-of-funder statement; the author contributions list who obtained funding but do not name a funder. Affiliations are not treated as the funder."
      }
    },
    "versionedRecordUrl": "https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.4.0&resultId=jama-intern-med-2024-realworld",
    "analysisPlanUrl": null,
    "analysisPlanSections": null,
    "registryCheckedOn": null,
    "detailUrl": "https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#jama-intern-med-2024-realworld"
  }
]
